Anthracyclines - Research News and Information

Wednesday, January 07, 2009

A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines.

6 Oct 2008 BACKGROUND: It was the aim of this study to evaluate the efficacy of docetaxel and vinorelbine combination in well-defined anthracycline-'exposed' or -'resistant' advanced breast cancer patients. PATIENTS AND METHODS: A phase II trial was carried ... Read more...

[Ventricular assist device implantation as a bridge to cardiac transplantation in two adolescents with end-stage cardiomyopathy and heart failure as a result of anthracycline use]

18 Sep 2008 In a adolescent women aged 15 and 17 years respectively, severe heart failure developed within a few months of anthracycline chemotherapy given for osteosarcoma. In the guidelines of the European Society of Cardiology, malignancy with a remission ... Read more...

Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity.

30 Aug 2008 Anthracycline-related cardiotoxicity has a substantial negative impact on long-term survivors of childhood cancer. The detection of cardiotoxicity is currently based on echocardiography or radionuclide angiography. However, as they depict only the ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Anthracyclines'

These are the very latest articles for this heading:

• A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines. 6 Oct 2008
• [Ventricular assist device implantation as a bridge to cardiac transplantation in two adolescents with end-stage cardiomyopathy and heart failure as a result of anthracycline use] 18 Sep 2008
• Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. 30 Aug 2008
• Chemotherapy-induced cardiotoxicity in women. 30 Aug 2008
• Novel targeting therapy concept for breast cancer treatment. 30 Aug 2008
• [A case of advanced small cell lung cancer complicated by chronic renal failure treated with amrubicin] 30 Aug 2008
• Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. 18 Aug 2008
• The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study. 3 Aug 2008
• Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. 30 Jul 2008
• Predicting and preventing the cardiotoxicity of cancer therapy. 30 Jul 2008
• Anthracycline cardiotoxicity: from bench to bedside. 30 Jul 2008
• Cardiovascular disease after hematopoietic cell transplantation--lessons learned. 30 Jul 2008
• Cured of Hodgkin lymphoma, but suffering a broken heart. 30 Jul 2008
• Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. 27 Jul 2008
• Anthracycline cardiotoxicity: one size does not fit all! 27 Jul 2008
• New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. 27 Jul 2008
• c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia. 22 Jul 2008
• Synergistic actions of a monooxygenase and cyclases in aromatic polyketide biosynthesis. 19 Jul 2008
• Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity. 9 Jul 2008
• Who should receive myeloablative therapy for diffuse large B-cell lymphoma? 6 Jul 2008

See a longer list of these articles.

Technical information about 'Anthracyclines'

Definition: Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.

Registry Number: 0

Descriptor UI: D018943

Alternative terms: Anthracyclines;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D02.455.426.559.847.562.050; D04.615.562.050; D09.408.051.059;

History Note: 96